200 related articles for article (PubMed ID: 34466656)
21. Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.
Park KS; Bazzill JD; Son S; Nam J; Shin SW; Ochyl LJ; Stuckey JA; Meagher JL; Chang L; Song J; Montefiori DC; LaBranche CC; Smith JL; Xu J; Moon JJ
J Control Release; 2021 Feb; 330():529-539. PubMed ID: 33358977
[TBL] [Abstract][Full Text] [Related]
22. Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and
Jawalagatti V; Kirthika P; Park JY; Hewawaduge C; Lee JH
J Adv Res; 2022 Feb; 36():211-222. PubMed ID: 35116175
[TBL] [Abstract][Full Text] [Related]
23. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
[TBL] [Abstract][Full Text] [Related]
24. Heterologous DNA-prime/protein-boost immunization with a monomeric SARS-CoV-2 spike antigen redundantizes the trimeric receptor-binding domain structure to induce neutralizing antibodies in old mice.
Pflumm D; Seidel A; Klein F; Groß R; Krutzke L; Kochanek S; Kroschel J; Münch J; Stifter K; Schirmbeck R
Front Immunol; 2023; 14():1231274. PubMed ID: 37753087
[TBL] [Abstract][Full Text] [Related]
25. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations.
Siriwattananon K; Manopwisedjaroen S; Shanmugaraj B; Prompetchara E; Ketloy C; Buranapraditkun S; Tharakhet K; Kaewpang P; Ruxrungtham K; Thitithanyanont A; Phoolcharoen W
Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358160
[TBL] [Abstract][Full Text] [Related]
27. Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice.
Mamedov T; Yuksel D; Ilgın M; Gurbuzaslan I; Gulec B; Yetiskin H; Uygut MA; Islam Pavel ST; Ozdarendeli A; Mammadova G; Say D; Hasanova G
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452461
[TBL] [Abstract][Full Text] [Related]
28. Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice.
Maltseva M; Galipeau Y; Renner TM; Deschatelets L; Durocher Y; Akache B; Langlois MA
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679875
[TBL] [Abstract][Full Text] [Related]
29. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.
Guo Y; He W; Mou H; Zhang L; Chang J; Peng S; Ojha A; Tavora R; Parcells MS; Luo G; Li W; Zhong G; Choe H; Farzan M; Quinlan BD
mBio; 2021 May; 12(3):. PubMed ID: 33975938
[TBL] [Abstract][Full Text] [Related]
30. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
31. Potent neutralization of SARS-CoV-2 including variants of concern by vaccines presenting the receptor-binding domain multivalently from nanoscaffolds.
Halfmann PJ; Castro A; Loeffler K; Frey SJ; Chiba S; Kawaoka Y; Kane RS
Bioeng Transl Med; 2021 Sep; 6(3):e10253. PubMed ID: 34589610
[TBL] [Abstract][Full Text] [Related]
32. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.
Pino M; Abid T; Pereira Ribeiro S; Edara VV; Floyd K; Smith JC; Latif MB; Pacheco-Sanchez G; Dutta D; Wang S; Gumber S; Kirejczyk S; Cohen J; Stammen RL; Jean SM; Wood JS; Connor-Stroud F; Pollet J; Chen WH; Wei J; Zhan B; Lee J; Liu Z; Strych U; Shenvi N; Easley K; Weiskopf D; Sette A; Pollara J; Mielke D; Gao H; Eisel N; LaBranche CC; Shen X; Ferrari G; Tomaras GD; Montefiori DC; Sekaly RP; Vanderford TH; Tomai MA; Fox CB; Suthar MS; Kozlowski PA; Hotez PJ; Paiardini M; Bottazzi ME; Kasturi SP
Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34266981
[TBL] [Abstract][Full Text] [Related]
33. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination.
Huang WC; Zhou S; He X; Chiem K; Mabrouk MT; Nissly RH; Bird IM; Strauss M; Sambhara S; Ortega J; Wohlfert EA; Martinez-Sobrido L; Kuchipudi SV; Davidson BA; Lovell JF
Adv Mater; 2020 Dec; 32(50):e2005637. PubMed ID: 33111375
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 spike antigen-specific B cell and antibody responses in pre-vaccination period COVID-19 convalescent males and females with or without post-covid condition.
Limoges MA; Quenum AJI; Chowdhury MMH; Rexhepi F; Namvarpour M; Akbari SA; Rioux-Perreault C; Nandi M; Lucier JF; Lemaire-Paquette S; Premkumar L; Durocher Y; Cantin A; Lévesque S; Dionne IJ; Menendez A; Ilangumaran S; Allard-Chamard H; Piché A; Ramanathan S
Front Immunol; 2023; 14():1223936. PubMed ID: 37809081
[TBL] [Abstract][Full Text] [Related]
36. Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.
Pitcovski J; Gruzdev N; Abzach A; Katz C; Ben-Adiva R; Brand-Shwartz M; Yadid I; Ratzon-Ashkenazi E; Emquies K; Israeli H; Haviv H; Rapoport I; Bloch I; Shadmon R; Eitan Z; Eliahu D; Hilel T; Laster M; Kremer-Tal S; Byk-Tennenbaum T; Shahar E
Vaccine; 2022 Feb; 40(8):1098-1107. PubMed ID: 35078662
[TBL] [Abstract][Full Text] [Related]
37. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
38. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
[TBL] [Abstract][Full Text] [Related]
39. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
[TBL] [Abstract][Full Text] [Related]
40. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]